Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published Date January 2007 Volume 2007:3(6) Pages 967—973

DOI

Published 15 January 2007

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab

Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K

International Journal of Nanomedicine 2015, 10:2173-2190

Published Date: 18 March 2015

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Schweizer A, Foley JE, Kothny W, Ahrén B

Vascular Health and Risk Management 2013, 9:57-64

Published Date: 15 February 2013

Characterization of drug-release kinetics in trabecular bone from titania nanotube implants

Aw MS, Khalid KA, Gulati K, Atkins GJ, Pivonka P, Findlay DM, Losic D

International Journal of Nanomedicine 2012, 7:4883-4892

Published Date: 12 September 2012

Glimepiride: evidence-based facts, trends, and observations

Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2012, 8:463-472

Published Date: 15 August 2012

Nanofiber composites containing N-heterocyclic carbene complexes with antimicrobial activity

Elzatahry AA, Al-Enizi AM, Elsayed EA, Butorac RR, Al-Deyab SS, Wadaan MAM, Cowley AH

International Journal of Nanomedicine 2012, 7:2829-2832

Published Date: 7 June 2012

Frontalis sling procedure for ocular myasthenia gravis

Asamura S, Kakizaki H, Enjyo M, Hashimoto T, Isogai N

Clinical Ophthalmology 2012, 6:575-577

Published Date: 12 April 2012

Retinopathy and risk factors in diabetic patients from Al-Madinah Al-Munawarah in the Kingdom of Saudi Arabia

El-Bab MF, Shawky N, Al-Sisi A, Akhtar M

Clinical Ophthalmology 2012, 6:269-276

Published Date: 17 February 2012

Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care

Frederic Kontny, Terje Risanger, Arne Bye, et al

Vascular Health and Risk Management 2010, 6:31-38

Published Date: 15 January 2010

Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial

Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-Pedersen

Vascular Health and Risk Management 2007, 3:31-37

Published Date: 18 May 2007